Kymera Therapeutics reported two early but impactful readouts: an oral candidate, KT‑621, produced a rapid clinical improvement in atopic dermatitis patients, and a separate STAT6 degrader program delivered biologics‑like biomarker activity in a Phase Ib study, according to company releases and BioCentury reporting. In a small Phase 1 BroADen study, 22 patients treated with KT‑621 experienced a mean 63% reduction in Eczema Area and Severity Index (EASI) after four weeks and two weeks of follow‑up. Separately, Kymera’s oral STAT6 degrader showed target engagement and biomarker changes that the company and analysts compared to injectable biologics. Degraders are small molecules designed to tag disease proteins for cellular disposal rather than simply blocking them; Kymera’s readouts suggest both modalities could deliver systemic immune control without antibody administration. The data remain early and will require larger trials to confirm clinical durability and safety.